1386O - Cancer cachexia (CAX), anorexia and muscle wasting (sarcopenia) assessment in non-small cell lung cancer (NSCLC): an observational study in 531 pa...

Date 09 September 2017
Event ESMO 2017 Congress
Session Supportive and palliative care
Topics Cancer in Adolescents
Palliative Care
Lung and other Thoracic Tumours
Palliative and Supportive Care
Presenter Didier Debieuvre
Citation Annals of Oncology (2017) 28 (suppl_5): v497-v501. 10.1093/annonc/mdx382
Authors D. Debieuvre1, H. Morel2, P. Souquet3, V. Surmont4, D. Planchard5, F. Bonnetain6, I. Krakowski7, H. Gaudin8, S. Antoun9
  • 1Department Of Pneumology, Hôpital Emile Muller, 68070 - Mulhouse/FR
  • 2Department Of Pneumology, C.H.R. Orleans - La Source, 45067 - Orleans/FR
  • 3Department Of Pneumology, Centre Hospitalier Lyon Sud, 69495 - Pierre Bénite/FR
  • 4Department Of Thoracic Oncology, Gent University Hospital, 9000 - Gent/BE
  • 5Department Of Medical Oncology, GUSTAVE ROUSSY, 94805 - Villejuif/FR
  • 6Methodological And Quality Of Life Unit In Oncology (inserm Umr 1098), CHRU Besançon Jean Minjoz, 25000 - Besançon/FR
  • 7Département Interdisciplinaire De Soins De Support Pour Le Patient En Oncologie. (disspo-care), Institut Bergonié, 33076 - Bordeaux/FR
  • 8Medical Affairs, Chugai Pharma France, 92042 - Paris/FR
  • 9Unité De Médecine Aigue En Oncologie, Institut Gustave Roussy, 94805 - Villejuif/FR

Abstract

Background

Since publications highlighting the role of sarcopenia, weight loss (WL) is no longer the corner stone of malnutrition assessment. An international consensus proposed in 2011 a definition and a staging of CAX, mainly based on WL, sarcopenia, inflammation and anorexia (Fearon). We initiated this study to fill the gap of epidemiological data on CAX in NSCLC in France and Belgium.

Methods

This cross-sectional, prospective, multicentric study was conducted in Patients (pts) with NSCLC regardless of the tumor stage and the treatment line. Skeletal muscle mass (SMM) was assessed by analyzing L3 CT-scan image. Pts completed Anorexia/CAX subscale of FAACT and EORTC QLQ-C30 health related quality of life (QoL) questionnaires. Primary endpoint was the frequency of CAX according to Fearon criteria. Secondary endpoints were the frequency and the characteristics of the other stages of CAX focusing on early and discrete malnutrition changes (pre-CAX).

Results

539 NSCLC pts were recruited within 3 months in 2016 by 56 sites, analysis population was of 531 pts and 312 had SMM assessment. Median age was 66 years, 66.5% were males, 79.9% were PS 

Conclusions

This is the first study showing an association between molecular abnormality in NSCLC and cachexia. It has also shown that it may be useful to detect sarcopenia in pts with limited WL (

Clinical trial identification

NCT02968979, First received: November 17, 2016

Legal entity responsible for the study

Chugai Pharma France

Funding

Chugai Pharma France

Disclosure

D. Debieuvre, P-J. Souquet, S. Antoun: Corporate-sponsored research: Chugai-Pharma France. H. Morel: Corporate-sponsored research: Chugai Pharma France, Roche, Astra, Lilly, MSD, Pfizer, BMS, amgen. V. Surmont: Corporate-sponsored research: Chugai-Pharma France. D. Planchard: Corporate-sponsored consultancy: AstraZeneca, Boehringer Ingelheim, BMS, Lilly, MSD, Pfizer, Roche, Novartis, Chugai Pharma France. F. Bonnetain: corporate-sponsored research: Chugai Pharma France, Amgen, Roche, Merck Serono, Nestlé, Ipsen, Jansen. I. Krakowski: Membership on an advisory board and/or symposium: Chugai Pharma France, Kyowa kirin, Pfizer, Astellas, Janssen, Takeda, P Fabre. H. Gaudin: Employee of Chugai Pharma France.